Home / Medical News / Physician’s Offices and Clinics Remain Largest Customer Base for Specialty Rx Distributors

Physician’s Offices and Clinics Remain Largest Customer Base for Specialty Rx Distributors

Center Research Highlights Latest Trends for Fast-Growing Specialty Market Segment

ARLINGTON, Va., February 3, 2015 — Physician’s offices and independently owned and operated physician clinics remain the largest customer base for specialty pharmaceutical distributors, at 63 percent of their sales value, according to the2014 Specialty Pharmaceutical Distribution: Facts, Figures and Trends, published by HDMA’s Center for Healthcare Supply Chain Research. The 2014 edition is sponsored by CuraScript Specialty Distribution, an Express Scripts Company; Genentech, A Member of the Roche Group; AstraZeneca Pharmaceuticals LP; and Pharmacy First.

The publication sheds light on the specialty Rx segment, which is valued at $207 billion globally and continues to grow at an unprecedented rate — a 3.9 percent compounded annual growth rate between 2008 and 2013, according to IMS Health. Based on primary survey data collected from HDMA specialty distributor members (who reported sales of $1 billion or more in 2013), as well as secondary data from leading healthcare organizations, this publication outlines major characteristics of the specialty segment — which focuses on the delivery of complex medications for those with chronic or rare diseases, many of which require special handling, storage, delivery and regulations. It also provides insight into the vital role of specialty distributors.

“The distribution-focused specialty research produced by the Center is highly valuable to CuraScript Specialty Distribution,” said Gayle Johnston, President, CuraScript Specialty Distribution and Chairman of the Center’s Board of Directors. “The bird’s-eye view provided by the 2014 Specialty Pharmaceutical Distributon book is very helpful as we gauge what is happening in our industry and improve the accuracy of our future plans.”

The increase in sales to physician’s clinics represents a 3 percentage point increase since the 2013 edition. Meanwhile, a decrease was seen in sales to hospitals (from 24 to 20 percent) and hospital-owned/operated and specialty clinics (from 11 to 10 percent of sales value). This may be due to provider consolidation related to reimbursement pressures (from commercial payers and Medicaid).

As noted in the report, oncology accounts for the highest in sales volume for specialty distributors (nearly 33 percent), but those falling outside of oncology, such as hemophilia (nearly 16 percent) and products categorized as “other” (nearly 17 percent) rounded out the top three categories. Along with oncology, medications in the inflammatory (e.g., Rheumatoid arthritis, Crohn’s disease) and hemophilia categories are those that specialty distributors believe are rising in importance.

The report further details the efficiencies and critical support specialty distributors provide to the healthcare supply chain. As documented in the 2014 report:

  • On average, a typical specialty distributor distributes to nearly 19,600 healthcare provider accounts, with more than 21,800 unique ship-to points.
  • Specialty distributors process on average nearly 3,400 orders daily, with nearly 12,000 lines picked each day and an average fill rate of 99 percent. The average turnaround time for delivering an order is less than 24 hours.
  • While specialty distributors are known for providing core services to ensure a secure supply chain, they also offer a comprehensive array of other professional services to support the use and delivery of these unique products, such as managing customer call centers, offering third-party logistics and recall services, reimbursement support, home delivery and consulting.

“This report adds to the resources the Center has developed to inform pharmaceutical supply chain stakeholders about the emerging specialty marketplace,” said Karen J. Ribler, Executive Vice President and COO of the Center for Healthcare Supply Chain Research. “With the continued growth of the industry, driven by new product launches, limited impact of patent expiries and increased demand for these products, we expect that there will be no shortage of topics for the Center to continue to explore in the coming years.”

The 2014 Specialty Pharmaceutical Distribution: Facts, Figures and Trends may be downloaded for $250 as a single-use PDF from E-junkie.com. Corporate-use licenses also are available. Visit the Center website for further details.

About the Center for Healthcare Supply Chain Research
The Center for Healthcare Supply Chain Research is a 501(c)(3) non-profit charitable organization that serves as the knowledge partner of the Healthcare Distribution Management Association (HDMA). The Center serves the healthcare industry by providing research and education focused on healthcare supply chain issues. The Center’s mission is two-fold: to conduct research and disseminate information that will enhance the knowledge base, efficiency and effectiveness of the total healthcare supply chain; and to provide thought leadership to further enhance the safety and security of the healthcare supply chain through future-focused study and programming.

About HDMA
HDMA is the national association representing primary healthcare distributors, the vital link between the nation’s pharmaceutical manufacturers and healthcare providers. Each business day, HDMA member companies ensure that 15 million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDMA and its members work daily to provide value and achieve cost savings, an estimated $42 billion each year to our nation’s healthcare system. For more information, visit www.HealthcareDistribution.org.

Check Also

Acceleron’s Investigational Muscular Dystrophy Therapy Fails to Achieve Functional Secondary Endpoints in Phase 2 Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development …

Leave a Reply

Your email address will not be published. Required fields are marked *